Shockingly, compound drug merchants allegedly lied when they sold accounts receivable to investors.
Who’da thunk it?
Thanks to Greg Jones of WorkCompCentral for his excellent investigative reporting on this. Greg reports that:
The basis for the case appears to be that Praxsyn allegedly didn’t tell Shadow Tree about pertinent details about the A/R deal, details such as the accusations about the source of the bills, the alleged nefarious activities of some of the parties involved and relevant lien settlement information.
I was peripherally involved in something similar to this, when a compounding company was trying to sell its receivables and a couple of potential buyers called me for my opinions.
Which, briefly summarized, were “run like hell.”
What does this mean for you?
That remains good advice for anyone approached by compounders, physician prescribing companies and so-called “revenue cycle management firms” doing most of their work in these areas.
Joe Paduda is co-owner of CompPharma, a consortium of pharmacy benefit managers. This column is republished with his permission from his Managed Care Matters blog.
May 13-15, 2024
Join us May 13–15, 2024, for NCCI's Annual Insights Symposium (AIS) 2024, the industry’s premier e …
Jul 29 – Aug 2, 2024
SAVE THE DATE! 76th Annual SAWCA Convention July 29 – August 2, 2024 Hotel Effie Sandestin 1 Grand …
Aug 14-17, 2024
California Society of Industrial Medicine and Surgery (CSIMS) is combining its two conferences, PI …
No Comments
Log in to post a comment